Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
Fehnel SE, McLeod LD, Brandman J, Arbit DI, McLaughlin-Miley CJ, Coombs JH, Martin AR, Girman CJ. Responsiveness of the acne-specific quality of life questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res. 2002 Dec 1;11(8):809-16.
Menter A, Gottlieb A, Griffiths C, Mordin MM. Health-related quality of life impact of weekly intravenous or intramuscular alefacept in patients with psoriasis: results from two randomized, placebo-controlled phase III trials. Poster presented at the Annual Meeting of the American Academy of Dermatology; February 2002.
Neighbors DM, Candrilli SD. Concomitant medication costing using clinical trial data: a case study. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000. Arlington, VA.
Steffensen FH, Sorensen HT, Gillman MW, Rothman KJ, Sabroe S, Fischer P, Olsen J. Low birth weight and preterm delivery as risk factors for asthma and atopic dermatitis in young adult males. Epidemiology. 2000 Mar;11(2):185-8.
Sorensen HT, Steffensen FH, Olsen J, Sabroe S, Gillman MW, Rothman KJ, Fischer P. Long-term follow-up of cognitive outcome after breech presentation at birth. Epidemiology. 1999 Sep 1;10(5):554-6.
McKenna SP, Koppeschaar HPF, Zelissen PMJ, Snel YEM, Whalley D, Doward LC. The impact of replacement gh on the quality of life of patients: results of a clinical trial in the Netherlands. Poster presented at the 22nd International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism; October 18, 1996. Vienna, Austria.